TRANSPOD
25.8.2020 13:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading hyperloop system (the TransPod system ) to disrupt and redefine commercial transportation, today announced it has signed a memorandum of understanding (MOU) with the Government of Alberta in Canada to support the development of safe, high-speed transportation in Alberta, based on the 1000 km/h TransPod vehicle. The MOU facilitates the process of attracting private investment to the province, in order to build a multi-billion-dollar infrastructure project. The project is estimated to create up to 38,000 jobs over 10 years, diversify Alberta’s economy, improve the efficient movement of people and goods, and reduce Alberta’s carbon emissions by up to 300,000 tonnes per year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005001/en/
The MOU will see Alberta Transportation:
- Support TransPod undertaking further study on the feasibility of developing its technology in Alberta
- Share available transportation data as appropriate that may assist TransPod in assessing the feasibility of its technology
- Work with TransPod officials to identify suitable land that can safely accommodate a test track
- Participate in discussions with potential large institutional investors where suitable
No financial commitments or endorsements have been made by Alberta Transportation regarding the TransPod project.
The phases of the Alberta TransPod project are as follows:
- Short-term: feasibility study (2020-2022)
- Short-term: research and development phase (2020-2024)
- Medium-term: test track construction and high-speed tests (2022-2027)
- Long-term: construction of a full inter-city line between Edmonton and Calgary (to begin in 2025)
“Alberta’s government is supporting new and exciting opportunities for job creation and innovation,” said Ric McIver, Alberta Minister of Transportation. “By supporting TransPod’s feasibility study, Alberta Transportation will provide important information contributing to the research, development, testing, and construction of a full inter-city TransPod line between Edmonton and Calgary. We look forward to seeing this work put Alberta on the forefront of the movement of goods and people.”
The TransPod system is being developed to carry passengers and cargo between cities at over 1000 km/h. Fossil-fuel-free and fully electric, it is a new generation of ultra-high-speed ground transportation being developed for construction around the world. It is built on a proprietary and innovative design that leverages aerospace engineering and is bolstered by a global network of engineering partners. The TransPod vehicle’s top speed is faster than a jet, and it travels at ground level in a protected guideway that is immune to weather. With the convenience of a subway that departs every few minutes, TransPod will avoid airline flight diversions, travel faster than a jet, and three times as fast as a high-speed train.
The TransPod vehicle’s innovative and cost-efficient design is a new leap forward for transportation that is clean, safe, cost-efficient, and comfortable. The company is developing this technology with high safety standards in collaboration with the European Union and United States transportation committees.
“Alberta’s leadership mindset and partnership with TransPod firmly places it at the cutting edge of transportation innovation,” said Sebastien Gendron, co-founder and CEO, TransPod. “Through this strategic agreement that secures the province’s economic future without having to commit any taxpayer dollars, the Government of Alberta is investing in improving growth and quality of life in the region.”
“The space race’s technology led to massive spinoffs worldwide, and our vision for TransPod is to position Canada at a similar level of leadership,” said Ryan Janzen, co-founder and CTO, TransPod. “Future transportation comes from breakthrough innovations — and that’s exactly what we’re doing.”
The TransPod system is being examined by governments and organisations for several projects around the world, and the company is currently in the design and development phase for a testing facility in France. The TransPod vehicle will also be featured in a demonstrator which will be showcased in Canada and France, to unveil new breakthroughs that are part of the 1000km/h TransPod system.
For more information:
TransPod project proposal to the Government of Alberta
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading hyperloop system (the TransPod System ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada.
For more information, visit https://transpod.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
